| Literature DB >> 28384360 |
Correction: Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo.
Anilkumar C Nirvanappa, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, Hanumappa Ananda, Alexey Yu Sukhorukov, Muthu K Shanmugam, Mahalingam S Sundaram, Siddaiah Chandra Nayaka, Kesturu S Girish, Arunachalam Chinnathambi, M E Zayed, Sulaiman Ali Alharbi, Gautam Sethi, Kanchugarakoppal S Rangappa.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0163209.].Entities:
Year: 2017 PMID： 28384360 PMCID： PMC5383341 DOI： 10.1371/journal.pone.0175659
Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240
Fig 1HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.
Histogram obtained indicated the accumulation cells in sub-G1 phase.
HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.
1. Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo.
Journal: PLoS One Date: 2016-09-29 Impact factor: 3.240